Kathryn Williams, MD
Urogynecology and Reconstructive Pelvic Surgery · Cary, NCNPI 1467689752
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,048 of the $2,679 with a category attached, or 76.5%. 19 manufacturers reported payments, led by Boston Scientific at 29.3% of the total. Reporting peaked in 2024 at $977 and has fallen 96.4% since, to $35 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in NC, where the typical reported total is $4,140.
Across 75 payments — averaging $35.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$786
- Coloplast$582
- Sumitomo Pharma America, Inc.$278
- Medtronic$223
- Myovant Sciences Inc.$120
- AbbVie$105
- plus $586 from 13 others
What the payments were for
- Travel & lodging$53120%
- Food & beverage$2,04876%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $786 |
| Coloplast | 3 | $582 |
| Sumitomo Pharma America, Inc. | 8 | $278 |
| Medtronic | 8 | $223 |
| Myovant Sciences Inc. | 7 | $120 |
| AbbVie(2 entities) | 4 | $105 |
| Astellas Pharma US Inc | 1 | $100 |
| Bayer | 4 | $87 |
| Therapeuticsmd, Inc. | 5 | $70 |
| Mayne Pharma Commercial LLC | 3 | $59 |
| Hologic Sales And Service, LLC | 3 | $52 |
| Organon | 3 | $50 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Evofem Biosciences, Inc. | 2 | $31 |
| Mycovia Pharmaceuticals, Inc. | 1 | $26 |
| Scynexis, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Axonics, Inc. | 1 | $19 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$531
- GENERAL FEMALE SUI$225
- Solyx SIS System$141
- GEMTESA$124
- ADVANTAGE$116
How this compares
$2,679 in reported general payments places this provider in the 45th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.
See all urogynecology and reconstructive pelvic surgery providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 85 | $59,568 |
| MyrbetriqMirabegron | 56 | $36,330 |
| Estradiol | 309 | $18,534 |
| PremarinEstrogens, Conjugated | 12 | $5,124 |
| Trospium Chloride ErTrospium Chloride | 22 | $3,964 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $1,743 |
| Solifenacin Succinate | 48 | $1,564 |
| Oxybutynin Chloride ErOxybutynin Chloride | 32 | $688 |
| NitrofurantoinNitrofurantoin Macrocrystal | 59 | $554 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 55 | $492 |
| Ibuprofen | 50 | $349 |
| Clobetasol Propionate | 16 | $348 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 16 | $245 |
| Cephalexin | 42 | $184 |
| Cyclobenzaprine Hcl | 55 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $278 | $59,56885 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $36,33056 claims |
| PfizerPremarin | $12 | $5,12412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.
Other urogynecology and reconstructive pelvic surgery in Cary
- Sarah BradleyCary$11K
- Christina KunyckyCary$4K
- Cary FishburneCharlotte$231K
- William PorterCharlotte$157K
- Catherine MatthewsWinston Salem$70K
- Erinn MyersCharlotte$30K
- Nazema SiddiquiDurham$29K
- Amie KawasakiDurham$27K
- Cindy AmundsenDurham$19K
- Rahul DuttaWinston Salem$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.